Boston Scientific Corporation (NYSE:BSX) Stock Has Consensus Target Price of $68.23 According to Brokerages

Key Points

• Boston Scientific has a “Moderate Buy” consensus rating from 31 analysts, with 25 buy ratings, three holds, two sells and one strong buy. The average 12-month price target is $68.23, above the reported share price of $45.67.
• Several brokerages recently lowered their price targets, including Canaccord Genuity to $66, Goldman Sachs to $57 and Truist Financial to $51, while Barclays upgraded the stock to “hold.”
• The company exceeded quarterly expectations with earnings of $0.86 per share versus the $0.83 consensus and revenue of $5.44 billion, up 7.5% year over year. Insiders also bought roughly $9.4 million of shares over the past 90 days.

Boston Scientific Corporation (NYSE:BSX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the thirty-one analysts that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating, twenty-five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $68.23.

BSX has been the subject of a number of recent research reports. Canaccord Genuity Group reduced their target price on shares of Boston Scientific from $70.00 to $66.00 and set a "buy" rating for the company in a research report on Thursday, July 30th. Weiss Ratings restated a "sell (d+)" rating on shares of Boston Scientific in a research report on Friday, October 2nd. The Goldman Sachs Group lowered their price target on shares of Boston Scientific from $71.00 to $57.00 and set a "buy" rating on the stock in a research report on Tuesday, July 14th. Truist Financial dropped their price objective on shares of Boston Scientific from $57.00 to $51.00 and set a "buy" rating for the company in a research note on Wednesday, October 14th. Finally, Barclays upgraded shares of Boston Scientific to a "hold" rating in a report on Wednesday, October 7th.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney purchased 186,240 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average price of $48.33 per share, with a total value of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares in the company, valued at $76,845,859.92. This trade represents a 13.27% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director David C. Habiger bought 2,100 shares of the business's stock in a transaction on Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 194,522 shares of company stock worth $9,385,210 in the last ninety days. Insiders own 0.34% of the company's stock.

Institutional Investors Weigh In On Boston Scientific

Hedge funds have recently modified their holdings of the company. Kelleher Financial Advisors purchased a new stake in shares of Boston Scientific during the 2nd quarter valued at approximately $25,000. Clal Insurance Enterprises Holdings Ltd acquired a new position in Boston Scientific in the first quarter valued at approximately $28,000. Nvwm LLC increased its stake in Boston Scientific by 526.2% during the third quarter. Nvwm LLC now owns 645 shares of the medical equipment provider's stock worth $28,000 after acquiring an additional 542 shares during the last quarter. Rakuten Securities Inc. acquired a new stake in Boston Scientific during the second quarter worth $30,000. Finally, Kings Path Partners LLC purchased a new stake in Boston Scientific in the third quarter valued at $31,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Stock Down 0.7%

NYSE BSX opened at $45.67 on Friday. The business has a fifty day moving average price of $45.46 and a 200 day moving average price of $49.16. Boston Scientific has a one year low of $41.38 and a one year high of $105.65. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. The company has a market cap of $66.19 billion, a P/E ratio of 18.49, a P/E/G ratio of 1.10 and a beta of 0.58.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts' consensus estimates of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%. The company had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the firm posted $0.75 EPS. The firm's revenue for the quarter was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts anticipate that Boston Scientific will post 3.24 EPS for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.